论文部分内容阅读
只有让不良企业付出高昂代价,才能让全体药企不敢掉以轻心,始终坚持“安全第一”。近日召开的国务院常务会议讨论通过了《国家药品安全规划(2011—2015年)》。其中一条重点内容备受各方关注:开展医药企业信用等级评价,对严重违规、失信者,将“行业禁入”。毋庸讳言,我国的药品安全现在还处于风险高发期。这些年来,“鱼腥草”事件、“欣弗”事件、“刺五加”事件……一次次刺痛着公众的神经,
Only to allow bad companies to pay a high price, so that all drug companies can not take it lightly, always adhere to “safety first ”. The State Council executive meeting recently held to discuss and adopt the “National Drug Safety Plan (2011-2015).” One of the key aspects of much attention by all parties: to carry out the credit rating of pharmaceutical companies, for serious violations, dishonesty, the “industry ban”. Needless to say, the drug safety in our country is still in a period of high risk. In recent years, “Houttuynia” events, “Xin Fu ” events, “Acanthopanaxes” incident ...... stabbed again and again the public’s nerves,